Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: A meta-analysis

American Journal of Gastroenterology

Volumn 107, Issue 12, 2012, Pages 1793-1801

  Lovell, Rebecca M ^a   Ford, Alexander C ^a,b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CLASSIFICATION; DIZYGOTIC TWINS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HEARTBURN; HUMAN; INTERVIEW; IRRITABLE COLON; MANNING CRITERIA; META ANALYSIS; MONOZYGOTIC TWINS; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; ROME I CRITERIA; ROME II CRITERIA; ROME III CRITERIA; SYSTEMATIC REVIEW; TELECONSULTATION;

GASTROESOPHAGEAL REFLUX; HUMANS; IRRITABLE BOWEL SYNDROME; ODDS RATIO; PREVALENCE; RESIDENCE CHARACTERISTICS; UNITED STATES;

EID: 84870840330     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.336     Document Type: Review

References (61)

1. Drossman DA, Th ompson WG, Talley NJ. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int 1990; 3: 159-72.
2. Th ompson WG, Irvine EJ, Pare P et al. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci 2002; 47: 225-35.
3. Ford AC, Marwaha A, Lim A et al. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010; 8: 401-9.
4. Ford AC, Suares NC, Talley NJ. Meta-analysis: the epidemiology of noncardiac chest pain in the community. Aliment Pharmacol Ther 2011; 34: 172-80.
5. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 1582-91.
6. Agreus L, Svardsudd K, Nyren O et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 671-80.
7. Agreus L, Svardsudd K, Talley NJ et al. Natural history of gastroesophageal reflux disease and functional abdominal disorders. Am J Gastroenterol 2001; 96: 2905-14.
8. Ford AC, Forman D, Bailey AG et al. Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. Aliment Pharmacol Ther 2008; 28: 1013-20.
9. Halder SLS, Locke GR III, Schleck CD et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 2007; 133: 799-807.
10. Ford AC, Forman D, Bailey AG et al. Irritable bowel syndrome: a 10-year natural history of symptoms, and factors that influence consultation behavior. Am J Gastroenterol 2008; 103: 1229-39.
11. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000; 14: 1589-94.
12. Kennedy TM, Jones RH, Hungin APS et al. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut 1998; 43: 770-4.
13. Locke GR III, Talley NJ, Fett SL et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
14. Chiocca JC, Olmos JA, Salis GB et al. Prevalence, clinical spectrum and atypical symptoms of gastro-oesophageal reflux in Argentina: a nationwide population-based study. Aliment Pharmacol Ther 2005; 22: 331-42.
15. Rey E, Elola-Olaso CM, Rodriguez-Artalejo F et al. Prevalence of atypical symptoms and their association with typical symptoms of gastroesophageal reflux in Spain. Eur J Gastroenterol Hepatol 2006; 18: 969-75.
16. Jones R, Lydeard S. Irritable bowel syndrome in the general population. Br Med J 1992; 304: 87-90.
17. Talley NJ, Zinsmeister AR, Van Dyke C et al. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101: 927-34.
18. Talley NJ, Zinsmeister AR, Melton LJ III. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142: 76-83.
19. El-Serag H, Hill C, Jones R. Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK general practice research database. Aliment Pharmacol Ther 2009; 29: 470-80.
20. Lembo A, Zaman M, Jones M et al. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: A twin study. Aliment Pharmacol Ther 2007; 25: 1343-50.
21. Manning AP, Th ompson WG, Heaton KW et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 277: 653-4.
22. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl II): II43-7.
23. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
24. Richter JE, Baldi F, Clouse RE et al. Functional oesophageal disorders. Gastroenterol Int 1992; 5: 3-17.
25. Clouse RE, Richter JE, Heading RC et al. Functional esophageal disorders. Gut 1999; 45 (Suppl II): II31-6.
26. Galmiche JP, Clouse RE, Balint A et al. Functional esophageal disorders. Gastroenterology 2006; 130: 1459-65.
27. Loney PL, Chambers LW, Bennett KJ et al. Critical appraisal of the health research literature: prevalence or incidence of a health problem. Chronic Dis Can 1998; 19: 170-6.
28. Higgins JPT, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-60.
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
30. Egger M, Davey-Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34.
31. Sterne JA, Sutton AJ, Ioannidis JP et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Br Med J 2011; 343: d4002.
32. Bolling-Sternevald E, Aro P, Ronkainen J et al. Do gastrointestinal symptoms fluctuate in the short-term perspective? The Kalixanda Study. Dig Dis 2008; 26: 256-63.
33. Cheung TK, Lam KF, Hu WHC et al. Positive association between gastrooesophageal reflux disease and irritable bowel syndrome in a Chinese population. Aliment Pharmacol Ther 2007; 25: 1099-104.
34. Drug VL, Oprea L, Bunescu D et al. The epidemiology of irritable bowel syndrome in an urban general population. Rom J Gastroenterol 2000; 9: 83-6.
35. Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol 2002; 97: 2290-9.
36. Lee SY, Lee KJ, Kim SJ et al. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion 2009; 79: 196-201.
37. Locke GR III, Zinsmeister AR, Talley NJ et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000; 75: 907-12.
38. Rajendra S, Alahuddin S. Prevalence of irritable bowel syndrome in a multi-ethnic Asian population. Aliment Pharmacol Ther 2004; 19: 707-8.
39. Reshetnikov OV, Kurilovich SA, Bobak M et al. [Gastrointestinal symptoms in adult population of Novosibirsk city: prevalence and risk factors]. Terapevticheskii Arkhiv 2009; 81: 11-6.
40. Sorouri M, Pourhoseingholi MA, Vahedi M et al. Functional bowel disorders in an Iranian population using Rome III criteria. Saudi J Gastroenterol 2010; 16: 154-60.
41. Talley NJ, Fett SL, Zinsmeister AR et al. Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology 1994; 107: 1040-9.
42. Zhao Y, Zou D, Wang R et al. Dyspepsia and irritable bowel syndrome in China: a population-based endoscopy study of prevalence and impact. Aliment Pharmacol Ther 2010; 32: 562-72.
43. Smart HL, Nicholson DA, Atkinson M. Gastro-oesophageal reflux in the irritable bowel syndrome. Gut 1986; 27: 1127-31.
44. Trimble KC, Farouk R, Pryde A et al. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995; 40: 1607-13.
45. Costantini M, Sturniolo GC, Zaninotto G et al. Altered esophageal pain threshold in irritable bowel syndrome. Dig Dis Sci 1993; 38: 206-12.
46. Zimmermann J, Hershcovici T. Bowel symptoms in nonerosive gastroesophageal reflux disease: nature, prevalence, and relation to acid reflux. J Clin Gastroenterol 2008; 42: 261-5.
47. Rubenstein JH, Nojkov B, Korsnes S et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 443-52.
48. Spiegel BMR, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol 2008; 103: 2972-6.
49. Lupascu A, Gabrielli M, Lauritano EC et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 1157-60.
50. Parodi A, Greco A, Savarino E et al. May breath test be useful in diagnosis of IBS patients? An Italian Study. Gastroenterology 2007; 132 (suppl 1): A192.
51. Ford AC, Spiegel BMR, Talley NJ et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 1279-86.
52. Posserud I, Stotzer P-O, Bjornsson ES et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007; 56: 802-8.
53. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintography and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011; 60: 334-40.
54. Lombardo L, Foti M, Ruggia O et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010; 8: 504-8.
55. Ratuapli SK, Ellington TG, O'Neill MT et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol 2012; 107: 730-5.
56. Kaji M, Fujiwara Y, Shiba M et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol 2010; 25: 1151-6.
57. Fujiwara Y, Kubo M, Kohata Y et al. Cigarette smoking and its association with overlapping gastroesophageal reflux disease, functional dyspepsia, or irritable bowel syndrome. Intern Med 2011; 50: 2443-7.
58. Talley NJ, Dennis EH, Schettler-Duncan VA et al. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003; 98: 2454-9.
59. Pimentel M, Rossi F, Chow EJ et al. Increased prevalence of irritable bowel syndrome in patients with gastroesophageal reflux. J Clin Gastroenterol 2002; 34: 221-4.
60. Heading RC, Monnikes H, Th olen A et al. Prediction of response to PPI therapy and factors influencing treatment outcome in patients with GORD: a prospective pragmatic trial using pantoprazole. BMC Gastroenterol 2011; 11: 52.
61. Wu JC, Lai LH, Chow DK et al. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil 2011; 23: 155-60.